



Duexis® (ibuprofen/famotidine) – First-time generic

- On August 4, 2021, [Alkem launched](#) an [AB-rated](#) generic version of Horizon's [Duexis \(ibuprofen/famotidine\)](#) tablets.
- Ongoing litigation continues with this launch.
- Duexis is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
- Duexis carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.